Liver iron deposits in hepatitis B patients: Association with severity of liver disease but not with hemochromatosis gene mutations

Journal of Gastroenterology and Hepatology (Australia)

Volumn 19, Issue 9, 2004, Pages 1036-1041

  Martinelli, Ana L C ^a   Araujo Filho, Antonio B ^a   Franco, Rendrik F ^a   Tavella, Marli H ^a   Ramalho, Leandra N Z ^a   Zucoloto, Sergio ^a   Rodrigues, Sandra S ^a   Zago, Marcos A ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Chronic hepatitis; Hepatitis B; HFE mutations; Liver iron deposits; Severity of liver disease

Indexed keywords

FERRITIN; HFE PROTEIN; IRON; LIVER ENZYME; TRANSFERRIN;

ADULT; ARTICLE; BIOCHEMISTRY; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; GENE MUTATION; HEMOCHROMATOSIS; HEPATITIS B; HISTOLOGY; HUMAN; HUMAN TISSUE; IRON BLOOD LEVEL; IRON STORAGE; LIVER BIOPSY; LIVER DISEASE; LIVER FIBROSIS; LIVER NECROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCORING SYSTEM; TRANSFERRIN BLOOD LEVEL;

EID: 4544323115     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2004.03410.x     Document Type: Article

References (37)

1. Sutnic AL, Blumberg BS, Lutsbader ED. Elevated serum iron levels and persistent Australian antigen (HBsAg). Ann. Intern. Med. 1974; 81: 855-6.
2. Zhou XD, De Tolla L, Custer RP, London WT. Iron, ferritin, hepatitis B surface and core antigens in the livers of Chinese patients with hepatocellular carcinoma. Cancer 1987; 59: 1430-7.
3. Di Bisceglie AM, Axiotis CA, Hoofnagle JH, Bacon BR. Measurements of iron status in patients with chronic hepatitis. Gastroenterology 1992; 102: 2108-13.
4. Hézode C, Cazeneuve C, Coué O et al. Liver iron accumulation in patients with chronic active hepatitis C: prevalence and role of hemochromatosis gene mutations and relationship with hepatic histological lesions. J. Hepatol. 1999; 31: 979-84.
5. Deugnier Y, Battistelli D, Jouanolle H et al. Serum HBV markers in genetic hemochromatosis: a study of 272 homozygous patients. J. Hepatol. 1991; 13: 286-90.
6. Beutler E, Gelbert T, West C et al. Mutation analysis in hereditary hemochromatosis. Blood Cells Mol. Dis. 1996; 22: 187-94.
7. Feder JN, Gnirke A, Thomas W et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat. Genet. 1996; 13: 399-408.
8. Merryweather-Clarke AT, Pointon JJ, Shearman JD, Robson KJH. Global prevalence of putative haemochromatosis mutations. J. Med. Genet. 1997; 34: 275-8.
9. Aguilar Martinez P, Biron C, Blanc F et al. Compound heterozygotes for hemochromatosis gene mutations: May they help to understand the pathophysiology of the disease? Blood Cells Mol. Dis. 1997; 23: 269-76.
10. Bacon BR, Faravesh MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994; 107: 1103-9.
11. Bonkovsky HL, Poh-Fitzpatrick M, Pimstone N et al. Porphyria cutanea tarda, hepatitis C and HFE gene mutations in North America. Hepatology 1998; 27: 1661-9.
12. Martinelli ALC, Zago MA, Roselino AMF et al. Porphyria cutanea tarda in Brazilian patients. Association with hemochromatosis C282Y mutation and hepatitis C virus infection. Am. J. Gastroenterol. 2000; 95: 3516-21.
13. Piperno A, D'Alba R, Fargion S et al. Liver iron concentration in chronic viral hepatitis: a study of 98 patients. Eur. J. Gastroenterol. Hepatol. 1995; 7: 1203-8.
14. Martinelli ALC, Franco RF, Villanova MG et al. Are haemochromatosis mutations related to the severity of liver disease in hepatitis C virus infection? Acta Haematol. 1999; 102: 152-6.
15. Knodell RG, Ishak KG, Black WC et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-5.
16. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19: 1513-20.
17. Sciot R, Van Eyken P, Facchetti F et al. Hepatocellular transferrin receptor expression in secondary siderosis. Liver 1989; 9: 52-61.
18. Miller SA. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988; 16: 1215.
19. Ludwig J, Hashimoto E, Porayko MK, Moyer TP, Baldus WP. Hemosiderosis in cirrhosis: a study of 447 native livers. Gastroenterology 1997; 112: 882-8.
20. Smith BC, Grove J, Guzail MA et al. Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C. Hepatology 1998; 27: 1695-9.
21. Piperno A, Vergani A, Malosio I et al. Hepatic iron overload in patients with chronic viral hepatitis: role of HFE gene mutations. Hepatology 1998; 28: 1105-9.
22. Riggio O, Montagnese F, Fiore P et al. Iron overload in patients with chronic viral hepatitis: how common is it? Am. J. Gastroenterol. 1997; 92: 1298-301.
23. Roberts AG, Whatley SD, Morgan RR, Worwood M, Elder GH. Increased frequency of the haemochromatosis C282Y mutation in sporadic porphyria cutanea tarda. Lancet 1997; 349: 321-3.
24. George DK, Goldwurm S, MacDonald GA et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998; 114: 311-18.
25. Stuart KA, Busfield F, Jazwinsk EC et al. The C282Y mutation in the haemochromatosis gene (HFE) and hepatitis C virus infection are independent cofactors for porphyria cutanea tarda in Australian patients. J. Hepatol. 1998; 28: 404-9.
26. Beinker NK, Voigt MD, Arendse M, Smith J, Stander IA, Kirsch RE. Threshold effect of liver iron content on hepatic inflammation and fibrosis in hepatitis B and C. J. Hepatol. 1996; 25: 633-8.
27. Bonkovsky HL. Iron as a comorbid factor in chronic viral hepatitis. Am. J. Gastroenterol. 2002; 97: 1-4.
28. Bonkovsky HL, Banner BF, Rothman AL. Iron and chronic viral hepatitis. Hepatology 1997; 25: 759-68.
29. Ishak KG. Light microscopic morphology of viral hepatitis. Am. J. Clin. Pathol 1976; 65: 787-827.
30. Farinati F, Cardin R, De Maria N et al. Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitis. J. Hepatol. 1995; 22: 449-56.
31. Kaplan J, Sarnaik S, Gitlin K et al. Diminished helper/suppressor lymphocyte ratios and natural killer cell activity in recipients of repeated blood transfusions. Blood 1984; 64: 308-10.
32. Ykura Y, Morimoto H, Johmura H, Fukui M, Sakurai M. Relationship between hepatic iron deposits and response to interferon in chronic hepatitis C. Am. J. Gastroenterol. 1996; 91: 1367-73.
33. Hayashi H, Takikawa T, Nishimura N, Yano M, Isomura T, Sakamoto N. Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron. Am. J. Gastroenterol. 1994; 89: 986-8.
34. Fontana RJ, Israel J, LeClair P et al. Iron reduction before and during interferon therapy of chronic hepatitis C. Results of a multicenter, randomized, controlled trial. Hepatology 2000; 31: 730-6.
35. Yano M, Hayashi H, Wakusawa S et al. Long term effects of phlebotomy on biochemical and histological parameters of chronic hepatitis C. Am. J. Gastroenterol. 2002; 97: 133-7.
36. vanThiel DH, Friedlander L, Fagiuoli S, Wright HI, Irish W, Gavaler JS. Response to interferon α therapy is influenced by the iron content of the liver. J. Hepatol. 1994; 20: 410-15.
37. Bayraktar Y, Saglam F, Temizer A, Uzunalimodlu B, van Thiel DH. The effect of interferon and desferrioxamine on serum ferritin and hepatic iron concentration in chronic hepatitis B. Hepatogastroenterology 1998; 45: 2322-7.